Key Insights

Highlights

Treatment Research

1 treatments under study, led by Nivolumab

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 1/2 (1)

Trial Status

Unknown1

Clinical Trials (1)

Showing 1 of 1 trials
NCT05887830Phase 1/2UnknownPrimary

Effect of Nivolumab vs Placebo in Patients With Acute Myocardial Infarction: A Randomized Clinical Trial

Showing all 1 trials

Research Network

Common Treatments

  • Nivolumab1

Active Sponsors

  • Second Affiliated Hospital, Zhejiang University, School of Medicine1

Top Investigators

  • Xinyang Hu, PhD1

    2nd Affiliated Hospital, School of Medicine, Zhejiang University, China

Activity Timeline